A Study to Evaluate the Safety and Effectiveness of WF10 Given to Patients With Late-Stage HIV Disease
NCT ID: NCT00002244
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
240 participants
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
WF10
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Are HIV-positive.
* Have a CD4 cell count of less than 50 cells/mm3 within 14 days prior to study entry.
* Are at least 18 years old.
* Have received anti-HIV drugs at some time in the past.
* Agree to practice abstinence or use effective methods of birth control, including the pill, during the study.
Exclusion Criteria
* Are being treated for any form of cancer within 30 days of study entry.
* Have ever received an HIV vaccine.
* Have received steroids within 30 days prior to study entry. (Note: Testosterone is allowed.)
* Have received certain medications, including anti-HIV treatments that are not approved by the FDA.
* Have participated in another WF10 study.
* Have an illness or any condition that might exclude them from this study.
* Are pregnant or breast-feeding.
* Abuse drugs or medications.
* Received a blood transfusion within 45 days prior to study entry.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
OXO Chemie
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Univ of Alabama at Birmingham
Birmingham, Alabama, United States
Tower Infectious Disease Med Ctr
Los Angeles, California, United States
Highland Gen Hosp / San Francisco Gen Hosp
Oakland, California, United States
ViRx Inc
San Francisco, California, United States
UCSF - San Francisco Gen Hosp
San Francisco, California, United States
George Washington Univ Med Ctr
Washington D.C., District of Columbia, United States
Univ of Miami School of Medicine
Miami, Florida, United States
Hillsborough County Health Dept
Tampa, Florida, United States
Ctr for Quality Care
Tampa, Florida, United States
AIDS Research Consortium of Atlanta
Atlanta, Georgia, United States
Leahi Hosp / Univ of Hawaii
Honolulu, Hawaii, United States
Northwestern Univ Med School
Chicago, Illinois, United States
Rush Med Ctr / Section of Infectious Diseases
Chicago, Illinois, United States
The CORE Ctr
Chicago, Illinois, United States
Univ of Iowa Hosp & Clinic
Iowa City, Iowa, United States
Boston Med Ctr / Clinical Research Office
Boston, Massachusetts, United States
Univ Health Ctr
Detroit, Michigan, United States
Regions Hosp
Saint Paul, Minnesota, United States
Truman Med Ctr / Infectious Disease Clinic
Kansas City, Missouri, United States
Newark Community Health Ctr
Newark, New Jersey, United States
Univ of New Mexico Health Science Center
Albuquerque, New Mexico, United States
Associates in Med and Mental Health
Tulsa, Oklahoma, United States
MCP Hahnemann Univ
Philadelphia, Pennsylvania, United States
Ludwig Lettau Private Practice
Charleston, South Carolina, United States
Burnside Clinic
Columbia, South Carolina, United States
Hampton Roads Med Specialists
Hampton, Virginia, United States
Virginia Mason Research Center / Clinical Trial Unit
Seattle, Washington, United States
St Paul's Hosp
Vancouver, British Columbia, Canada
QEII Health Science Centre
Halifax, Nova Scotia, Canada
Ottawa General Hospital
Ottawa, Ontario, Canada
Sunnybrook Health Science Ctr
Toronto, Ontario, Canada
Montreal Gen Hosp / Div of Clin Immuno and Allergy
Montreal, Quebec, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
222C
Identifier Type: -
Identifier Source: org_study_id